Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.64 |
| ▸ | CES1 | P23141 | 4/20 | 0.64 |
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6831741 | 0.97 | CES2 (0.61) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL15020381 | 0.84 | CES2 (0.46) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL30326069 | 0.82 | HDAC1 (0.59) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL811633 | 0.82 | PARP1 (0.45) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL4346184 | 0.82 | PTPN11 (0.53) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL628083 | 0.81 | CES2 (0.43) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL1004335 | 0.80 | HDAC1 (0.57) | CES2CES1PARP1PTPN11CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL30849240 | 0.80 | PTPN11 (0.51) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL3783315 | 0.80 | PARP1 (0.43) | CES2CES1PARP1PTPN11CYP3A4 | |
| SCHEMBL2095495 | 0.79 | CES2 (0.64) | CES2CES1PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754797-B | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118754797-A | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-117979712-A | Wide-bandgap trans-perovskite solar cell and preparation method thereof | 武汉理工大学 | 2024-05-03 | — | — | CN | claimed |
| JP-2002532414-A | — | — | 2002-10-02 | — | — | JP | claimed |
| EP-1140046-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| CN-118754797-B | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118754797-A | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117979712-A | Wide-bandgap trans-perovskite solar cell and preparation method thereof | 武汉理工大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-117979712-A | Wide-bandgap trans-perovskite solar cell and preparation method thereof | 武汉理工大学 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024028243-A1 | PYRAZOLO PESTICIDAL COMPOUNDS | BASF SE (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-10738035-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20090105345-A1 | AMIDE LINKED MODULATORS OF Gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-5565614-A | FLUORINATION | BAYER AKTIENGESELLSCHAFT (DE) | 1996-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152236-A1 | Cyclic amine compound | AR, FSHR, NR5A1 | CES2 3854/4885CES1 1551/4885PARP1 2731/4885 |
| US-10738035-B2 | Hepatitis B antiviral agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | CES2 2136/4885CES1 71/4885PARP1 2426/4885 |
| US-20090105345-A1 | AMIDE LINKED MODULATORS OF Gamma-SECRETASE | BACE1, BACE2, APH1A | CES2 844/4885CES1 123/4885PARP1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.